Autoantibodies ot protnrombin and phosphatidylserine/prothrombin-complexes: Do they contribute to the serodiagnosis of primary and secondary anti-phospholipid syndrome?

Clinical Laboratory

Volumn 50, Issue 5-6, 2004, Pages 295-304

  Jaekel, H P ^a   Trabandt, A ^c   Schmid, D ^b   Grobe, N ^a   Muller E W ^a   Ziutelis, V ^a   Kaskel Paul, S ^a   Hoh H ^a   Bauer, B ^a   Sudik, R ^a   Baldauf, A ^d   Werle, E ^a  

^a Dietrich Bonhoeffer Clinical Centre   (Germany)

^b Dietrich Bonhoeffer Clinical Centre   (Denmark)

^c Hospital Demmin   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Anti phosphatidylserine prothrombin Ab; Anti prothrombin Ab; Clinical and diagnostic relevance for APS; Reactivity profiles

Indexed keywords

ANTIGEN; AUTOANTIBODY; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY; PROTHROMBIN;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL FEATURE; COMPLEX FORMATION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SEROPREVALENCE; SYMPTOMATOLOGY; CROSS REACTION; IMMUNOLOGY; MIDDLE AGED; SEROLOGY;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; CROSS REACTIONS; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PHOSPHATIDYLSERINES; PROTHROMBIN; SEROLOGIC TESTS;

EID: 16544390939     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hughes GRV. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br.Med.J. 1983; 187: 1088-9
2. Wilson WA, Ghavari AE, Koike T et al. International consensus statement on preliminary classification criteria for definite anti-phospholipid syndrome. Arthr.Rheum. 1999; 42: 1309-11
3. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant: An update. Thromb.Haemost. 1995; 74: 1185-90
4. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc.Natl.Acad.Sci.USA 1990; 87: 4120-24
5. Galli M, Comfurius B, Maassen C et al. Anticardiolipin antibodies directed not to cardiolipin butto plasma protein cofactor. Lancet 1990; 335: 1544-7
6. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb. Haemost. 1991; 66: 629-32
7. Matsuda J, Saitoh N, Gotoh M, Kawasugi K, Ghochi K, Tsukamoto M. Phosphatidylserine-dependent antiprothrombin antibody is exclusive to patients with lupus anticoagulant. Br.J. Rheumat. 1996; 35: 589-91
8. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, Koike T. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthr.Rheum. 2000; 43: 1982-93
9. Palosuo T, Virtamo J, Haukke J, Taylor PR, Puurunen M, Vaarala O. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men - a nested case-control study. Thromb.Haemost. 19997; 78: 1178-82
10. Inanc M, Donohoe S, Ravirajan CT, Radway-Bright EL, Mackie I, Machin S, Isenberg DA. Anti-β2-glycoprotein I, anti-prothrombin and anti-cardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br.J. Rheumat. 1998; 37: 1089-94
11. Forastiero R, Martinuzzo M, Adamczuk Y, Carreras LO. Occurrence of anti-prothrombin and anti-β2-glycoprotein I antibodies in patients with history of thrombosis. J.Lab.Clin.Med. 1999; 134: 610-15
12. Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M, Bodolay E, Szucs G, Szakony S, Sipka S, Szegedi G. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. J.Rheumat. 2000; 27: 924-9
13. Musial J, Swadzba J, Motyl A, Iwaniec T. Clinical significance of antiphospholipid-protein antibodies. Receiver operating characteristics plot analysis. J.Rheumat. 2003; 30: 723-30
14. Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome? J.Autoimmun. 2000; 15: 101-5
15. Pierangeli SS, Ghavari AE, Harris EN. Anticardiolipin testing. In: Kamashta MA, Munther A (eds): Hughes Syndrome. Berlin-Heidelberg-New York: Springer, 2000: 205-13
16. Galli M, Barbui T. Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome. Clin.Chem. 2001; 47: 985-7
17. Previtali S, Barbui T, Galli M. Anti-β2-glycoprotein I and antiprothrombin antibodies in anti-phospholipid-negative patients with thrombosis. Thromb.Haemost. 2002; 88: 729-32
18. Roubey RAS. Update on antiphospholipid antibodies. Curr. Opin. Rheumatol. 2000; 12: 374-8
19. Jackel HP, Schmid D, Müller E-W, Ziutelis V, Trabandt A, Grobe N, Kaskel-Paul S, Höh H, Bauer B, Sudik S, Baldauf A, Werle E. Reactivity profiles of autoantibodies to different phospholipids and the phospholipid-binding protein β2-glycoprotein I in patients with clinical symptoms related to thromboembolic and/or vasculopathic events with or without connective tissue diseases. Clin.Lab. 2003; 49: 345-55
20. Jaekel HP, Klopsch T, Benkenstein B, Grobe N, Baldauf A, Schoessler W, Werle E. Reactivities to the Sm autoantigenic complex and the synthetic SmD1-aa83-119 peptide in systemic lupus erythematosus and other autoimmune diseases. J.Autoimmun. 2001; 17: 347-54
21. Akimoto T, Akama T, Kono I, Yamanc K, Sumida T. Detergent and antigen fragility affect the ELISA for measurement of antiprothrombin autoantibodies. J.Rheum. 1999; 26: 580-7
22. Tripodi A, Mannucci PM. Laboratory invstigation of thrombophilia. Clin.Chem. 2001; 47: 985-7
23. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Iwatani Y, Kanakura Y. Association between the prevalence of antibodies to β2-glycoprotein I, prothrombin, protein C, protein S and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin.Chem. 2001; 47: 1008-15
24. Moscicki RA, San Martin JE, Quintero CH, Rauch SD, Nadol JB, Bloch KJ. Serum antibodies to inner ear proteins in patients with progressive hearing loss. JAMA 1994; 272: 611-6
25. Casoli P, Tumiati B. Cogan's syndrome: a new possible complication of antiphospholipid antibodies? Clin.Chem. 1995; 14: 197-8
26. Castanon C, Amigo MC, Banales JL, Nava A, Reyes PA. Occular vaso-occlusive disease in primary anti-phospholipid syndrome. Ophthalmol. 1995; 102: 256-62
27. Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T, Iwatani Y, Kanakura Y. Acquired activated protein C resistance is associated with the coexistence of antiprothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br.J.Haematol. 2002; 118: 577-83
28. Pasquier E, Amiral J, de Saint Martin L, Mothier D. A cross-sectional study of antiphospholipid -protein antibodies in patients with venous thromboembolism. Thromb. Haemost. 2001; 86:538-42
29. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Kitani T, Iwatani Y, Kanakura Y. Anti-prothrombin antibodies combined with lupus anticoagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br.J.Haematol. 2001; 114: 647-54
30. Zhao Y, Rumold R, Zhu M, Zhou D, Ahmed AE, Le DT, Hahn BH, Woods VL, Chen PP. An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthr.Rheum. 1999; 42: 2132-8
31. Simmelink Mj, Morbach DA, Derksen RH, Meijers Jc, Bevers EM, Willems GM, DeGroot PG. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br.J. Haematol. 2001; 113: 621-9
32. Madoura S, Nakamura Y, Mimaro J, Furusawa S, Koyama T, Sugo T, Matsuda M, Sakata Y. Autoantibody against prothrombin aberrantly alters the proenzyme to facilitate formation of a complex with its physiological inhibitor antithrombin III without thrombin conversion. Blood 2001; 97: 3783-9
33. Field SL, Chesterman CN, Dai YP, Hogg PJ. Lupus antibody bivalency is required to enhance prothrombin binding to phospholipid. J.Immunol. 2001; 166: 6118-25